Phase 2 Trial Results Show First-in-Class Drug Sotatercept Successfully Reduces Pulmonary Pressure in Heart Failure Patients

ACC.26 trial shows sotatercept significantly reduces pulmonary vascular resistance and improves heart function in CpcPH-HFpEF patients.

By: AXL Media

Published: Mar 30, 2026, 4:01 AM EDT

Source: Information for this report was sourced from American College of Cardiology

A Potential Breakthrough for Treatment-Resistant Pulmonary Hypertension

Medical professionals are reporting a significant milestone in the treatment of a complex cardiovascular condition that has long lacked effective therapies. According to Mardi Gomberg, a cardiologist at the George Washington School of Medicine and Health Sciences, the drug sotatercept has shown remarkable promise in treating patients with Group 2 pulmonary hypertension. Specifically, the study focused on individuals with heart failure with preserved ejection fraction, or HFpEF, who also suffer from severe vascular damage in the lungs. This condition, known as CpcPH, occurs when high pressure from the left side of the heart backflows into the pulmonary system, causing permanent damage to the lung's blood vessels and severely limiting a patient's quality of life.

Mechanisms of Action in Abnormal Vascular Cell Proliferation

Sotatercept represents a new class of pharmaceutical intervention designed to target the underlying biological causes of vessel narrowing. While the drug is already approved for Group 1 pulmonary hypertension, which is often genetic or systemic, its application in heart-failure-related lung pressure is entirely novel. The medication works by inhibiting the abnormal proliferation of cells within the blood vessel walls, effectively preventing the thickening and stiffening that makes it difficult for the heart to pump blood. By addressing the cellular structure of the pulmonary vasculature, the drug aims to reverse the "stiffening" that characterizes HFpEF, where the heart's left ventricle fails to relax and fill properly between beats.

Quantifying Vascular Improvements in the CADENCE Trial

The Phase 2 trial, which enrolled 164 participants with an average age of 75, utilized a randomized, placebo-controlled design to measure the drug's efficacy over 24 weeks. The primary success of the study was a significant reduction in pulmonary vascular resistance, a critical metric that measures the strain placed on the heart as it moves blood through the lungs. Researchers observed that patients taking sotatercept experienced a notable decrease in this resistance, suggesting that the pulmonary arteries were becoming more flexible and open. Gomberg noted that these hemodynamic improvements were accompanied by better right heart function and a decrease in clinical worsening events...